CVS · NYSE · STOCK
CVS Health (CVS) Stock Analysis
$93.03
52W $69.51 – $110.68
53/100
$118.69B
24.3
0.60
Is CVS Bullish or Bearish?
Mixed.
Innellis AI committee rates CVS Health (CVS) Watch with a composite score of 53/100
, based on 6 analysts with 50% agreement.
Last updated August 23, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +7.08 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -12.92 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Risk Analyst remains cautious — current ratio of 0.84 is tight -- limited short-term liquidity cushion. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Price-to-book of 1.3x is a discount to asset value — Value
- Dividend yield of 3.5% pays you to wait — Value
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- P/E of 25.0 is moderate-to-rich — Value
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- MACD histogram negative -- bearish momentum — Technical
- Current ratio of 0.84 is tight -- limited short-term liquidity cushion — Risk
- Bollinger bandwidth of 22.5% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 23, 2026
Overall Committee Score
53/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 84%
of 192 Healthcare peers
Value Analyst
bullish
60
/ 100 · Moderate confidence
Classic value case: cheap on multiples with earnings power to back it up
+ Price-to-book of 1.3x is a discount to asset value
− P/E of 25.0 is moderate-to-rich
Growth Analyst
neutral
52
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ 5 consecutive earnings beats -- consistent execution
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
neutral
48
/ 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst
bearish
35
/ 100 · Moderate confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Current ratio of 0.84 is tight -- limited short-term liquidity cushion
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 3069.37)
Investment Thesis Evolution
Committee score moved marginally from 52.9 to 52.9.
Comparing 2026-08-22 to 2026-08-23 (1 day apart).
Technical Analysis
RSI (14)
30.0
Oversold
MACD Histogram
-0.574
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Hh Hl
Support
$88.81
Resistance
$96.53
Bollinger %B
0.24
Inside Bands
Price vs Moving Averages
EMA 9
$94.90
Below
EMA 21
$97.81
Below
EMA 50
$98.69
Below
EMA 200
$87.98
Above
Fundamental Analysis
Valuation
54
Growth
75
Profitability
6
Financial Health
41
Cash Flow
70
Valuation
P/E Ratio
24.3×
P/B Ratio
1.49×
PEG Ratio
3.80
Dividend Yield
2.86%
52W High
$110.68
52W Low
$69.51
Quality & Growth
ROE
235.1%
ROA
67.7%
Gross Margin
1415.3%
Operating Margin
199.7%
Revenue Growth YoY
—
Debt / Equity
0.96
AI Fundamental Assessment
P/E ratio of 24.3 (inexpensive relative to a 15-40x range); Price-to-book of 1.5x; PEG ratio of 3.8 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 2.4%; Return on assets of 0.7%; Net margin of 1.2%; Gross margin of 14.2%; Current ratio of 0.87 (tight short-term liquidity); Debt-to-equity of 0.96; Free cash flow per share is positive (9.21); Most recent quarter beat estimates by 38.0%; 5 consecutive earnings beats; EPS growth decelerating (+135.8% -> +0.4% QoQ); Average YoY EPS growth of 42.5%; Analyst estimates rising over recent quarters
Get the Full CVS Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →